Previous 10 | Next 10 |
In a letter to shareholders, Bristol-Myers Squibb (NYSE: BMY ) reiterates the benefits of its $74B bid for Celgene (NASDAQ: CELG ). Key points: More news on: Bristol-Myers Squibb Company, Celgene Corporation, Healthcare stocks news, Merger & acquisition news, Read more ...
Urges Shareholders to Vote “FOR” the Proposed Transaction on the WHITE Proxy Card Bristol-Myers Squibb Company’s (NYSE:BMY) Board of Directors today sent an open letter to the Company’s shareholders regarding the previously announced definitive merger agr...
Back in early January, Bristol-Myers Squibb Co. ( BMY ) made an offer to acquire Celgene Corp. ( CELG ). Several S.A. authors contributed thoughtful commentaries reflecting upon the April 12 shareholder voting outcome. If affirmative, the voting will clear the way for a third-quarter closing...
February monthly performance was: -1.64% More news on: IQ ARB Merger Arbitrage ETF, Red Hat, Inc., L3 Technologies, Inc., Read more ...
In an interview on CNBC, Starboard Value's Jeff Smith reiterated his opposition to Bristol-Myers Squibb's ( BMY -0.8% ) announced $74B takeover of Celgene ( CELG -1.2% ), citing its over-generous bid considering CELG's looming patent cliff and doubts that it will be able to produce 10 ...
Thinking about pipelines One of the ongoing lessons I take from observing the business world is the importance of a company taking prudent risks. Another observation as an investor is the value of companies that under-promise and over-deliver. The Biogen ( BIIB ) stock crash Thursday on t...
British pharma GlaxoSmithKline (NYSE: GSK) joined the recent groundswell of high-grade corporate bond issuers Monday to sell new debt. The UK-based firm priced US$3.5bn worth of ‘A’-rated, three-, five- and 10-year notes to help pay for its estimated US$5.1bn purchase of oncolo...
The proposed cash and stock acquisition of Celgene ( CELG ) by Bristol-Myers Squibb ( BMY ) saw the former's share price jump up from $66.64 on January 2 to $80.43 on January 3. Bristol-Myers Squibb has offered a total consideration of around $74 billion for Celgene. Based on the closing p...
Introduction Although many Health Technology Sector companies have significantly outperformed the market on a long-term basis, they have significantly underperformed the market since the beginning of 2015. With only a few minor exceptions, this is true for most companies, especially the ph...
Quick Take Precision BioSciences ( DTIL ) intends to raise $126 million in an IPO of its common stock, per an amended registration statement . The company has created an advanced gene-editing platform for a variety of disease conditions and crop modification purposes. DTIL has promising...
News, Short Squeeze, Breakout and More Instantly...
Celgene Corporation Company Name:
CELG Stock Symbol:
NASDAQ Market:
In this clip from "The Pharma & Biotech Show" on Motley Fool Live , recorded on Feb. 2 , Motley Fool contributor Brian Orelli analyzes Gilead 's (NASDAQ: GILD) earnings report and discusses why the biotech giant could see fairly low revenue growth or even see earnings dr...
What coronavirus? Amgen 's (NASDAQ: AMGN) latest set of quarterly figures, delivered Tuesday, showed growth in the company's fundamentals during a challenging time for companies across all economic sectors. The veteran biotech company booked revenue of nearly $6.21 billion in the second qu...
It's scary out there right now for investors, with wild market swings and a lot of negative news coming out of quarterly reports. There is one sector, however, that will survive and likely thrive despite the coronavirus pandemic shutdown -- healthcare. That said, investors shouldn't head for jus...